Multinational study exploring patients’ perceptions of side-effects induced by chemo-radiotherapy

Ruhlmann, Christina H; Iversen, Trine Zeeberg; Okera, Meena; Muhic, Aida; Kristensen, Gunnar B.; Feyer, Petra; Hansen, Olfred; Herrstedt, Jørn

doi:10.1016/j.radonc.2015.09.014

Cited by 25 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in line with a prospective study in patients receiving fractionated radiotherapy and concomitant weekly cisplatin (98% received antiemetic prophylaxis; 98% received a 5-HT 3 RA, 96% received a corticosteroid, and 38% received a NK 1 RA), where 71% and 36% of patients suffered from nausea and vomiting, respectively, during treatment, and patients ranked nausea as the fifth most distressing symptom [29].…”

Section: Expert Opinionsupporting

confidence: 84%

See 1 more Smart Citation

New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting

Ruhlmann

Herrstedt

2016

Expert Opinion on Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

Antiemetic prophylaxis for patients receiving concomitant chemoradiotherapy has, for many years, been an orphan research area. The distinction between acute and delayed nausea and vomiting does not apply to fractionated radiotherapy, and prophylaxis should be considered to cover the entire course of treatment and not only the acute and delayed chemotherapy-induced nausea and vomiting. The best prophylaxis in women receiving fractionated radiotherapy and concomitant weekly cisplatin is a combination of the neurokinin receptor antagonist fosaprepitant with palonosetron and dexamethasone. Even with this three-drug combination nausea is a significant problem and the effect of multi-receptor targeting antiemetics such as olanzapine and amisulpride should be explored in this setting.

show abstract

Section: Expert Opinionsupporting

confidence: 84%

“…Future antiemetic trials should include nausea as the primary endpoint as nausea clearly is more bothersome to patients compared to vomiting [29]. Antiemetic studies in chemo-radiotherapy should evaluate the entire course of treatment, i.e.…”

Section: Expert Opinionmentioning

confidence: 99%

New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting

Ruhlmann

Herrstedt

2016

Expert Opinion on Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…[8][9][10] Radiation-induced nausea and vomiting (RINV) also has a signifcant adverse efect on life qualit y. [11][12][13] Few reported clinical trials have provided efective prevention or treatment recommendations for RINV. [14][15][16] Concurrent chemotherapy radiotherapy is commonly used for locally advanced head and neck cancers 17 and locally advanced esophageal cancers.…”

mentioning

confidence: 99%

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

Navari¹,

Nagy²,

Le‐Rademacher³

et al. 2016

J Community Support Oncol

View full text Add to dashboard Cite

“…Although cancer treatments have undergone massive developments in recent year, cancer remains a difficult disease to solve worldwide. Traditional cancer therapies, such as clinical operation, chemotherapy, and radiotherapy, may have a curative effect in the short term but will cause side effects, decreasing cancer patient quality of life [1]. Immunotherapy has been recognized as a new generation of an antitumor weapons and will be the leading force in future cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead

Zhang

Ping

Huang

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. Like other technologies, CAR-T cell therapy has undergone a long development process, and persistent explorations of the actions of the intracellular signaling domain and make several improvements have led to the superior efficacy when anti-CD19 CAR-T cell treatments in B cell cancers. At present, CAR-T cell therapy is developing rapidly, and many clinical trials have been established on a global scale, which has great commercial potential. This review mainly describes the toxicity of CAR-T cell therapy and the challenges of CAR-T cells in the treatment of solid tumors, and looks forward to future development and opportunities for immunotherapy and reviews major breakthroughs in CAR-T cell therapy.

show abstract

Multinational study exploring patients’ perceptions of side-effects induced by chemo-radiotherapy

Cited by 25 publications

References 18 publications

New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting

New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead

Contact Info

Product

Resources

About